Drug details

Vivimusta (bendamustine hydrochloride injection)

type of Antineoplastics, Alkylating

Vivimusta (bendamustine hydrochloride injection) is an alkylating drug indicated for treatment of patients with chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fever, and
• high blood pressure

The following drugs are related to Vivimusta, either as a replacement or used together:

• Arzerra (ofatumumab injection)
• Bendeka (bendamustine hydrochloride injection)
• Leukeran (chlorambucil)
• Copiktra (duvelisi capsules)
• Gazyva (obinutuzumab injection)
• Imbruvica (ibrutinib capsules)
• Zydelig (idelalisib tablets)
• Riabni (rituximab-arrx injection)
• Truxima (rituximab-abbs injection)
• Ruxience (rituximab-pvvr injection)
• Venclexta (venetoclax tablets)